Abstract
Background In developing countries, the high mortality of breast cancer (BC) patients is strongly related to delayed presentation and subsequent advanced stage diagnosis, pointing to the need for improved detection programs. This study aims to assess the prevalence and factors associated with delayed presentation of BC patients at Hawassa University Oncology Center (HUOC), Hawassa, Ethiopia.
Methods A cross-sectional institution-based survey was conducted among BC patients between May 1st and August 30th, 2021. BC patients attending HUOC were included by consecutive sampling. Data was collected using an interviewer-administered questionnaire and medical record data extraction. A multivariable binary logistic regression model was carried out to identify associations between delayed presentation and potential risk factors.
Results A total of 150 BC patients participated in the study giving a response rate of 100%. Of these, 86 (57.3%) women presented with a long delay of ≥ 3 months. The median time to visit a health care provider after recognition of the first symptoms was 5.5 months. Urban residence (adjusted odds ratio (AOR) = 0.42; 95 %-CI=0.18-0.97) and not visiting of traditional healer (AOR=0.15, 95 %-CI=0.07-0.34) was associated with shorter delay time. No breast pain symptoms (AOR=8.57; 95 %-CI=3.47-21.15), no family history of BC (AOR=5.12; 95 %-CI=1.36-19.33), and travel distance ≥ 5 km (AOR=3.00, 95 %-CI=1.25-7.21) were associated with longer delay in presentation.
Conclusion A substantial proportion of patients with BC in southern Ethiopia have delays in seeking medical care. Interventional programs like public BC awareness campaigns are strongly needed to reduce delayed presentation and to increase early detection of cancer cases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
this fund was supported by Else Kröner-Fresenius-Stiftung. The funder had no role in study design, data collection. Grant number is not applicable
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical clearance was obtained from Hawassa University College of medicine and health science, institutional review board. A formal letter of cooperation to conduct this research was written to HUCSH cancer treatment center. Verbal and written consent was obtained from each respondent
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available upon reasonable request.
Abbreviations
- AOR
- adjusted odds ratio
- ETB
- Ethiopian birr
- HUCSH
- Hawassa university comprehensive specialized hospital
- SPSS
- statistical package for social science
- HUOC
- Hawassa University Oncology Center
- TASH
- Tikur Anbessa specialized hospital.